However, if we obtain the same value, this does not necessarily mean that it is the most accurate one. We thank the Association pour la Recherche en Médecine Foetale for financial support and all of the manufacturers who contributed software packages. We also thank Lau-rence Bussière, who was involved in the early stages of this work. diagnosis of diverse chromosome abnormalities in a populatio...

OBJECTIVES To investigate whether the addition of maternal serum placental growth factor (PlGF) measured at 11-13 weeks' gestation improves the performance of screening for stillbirths that is achieved by a combination of maternal factors and first-trimester biomarkers such as maternal serum pregnancy-associated plasma protein-A (PAPP-A), fetal ductus venosus pulsatility index for veins (DV-PIV...

OBJECTIVE To investigate the performance of first-trimester screening for aneuploidies by including assessment of tricuspid blood flow in the combined test of maternal age, fetal nuchal translucency (NT) thickness, fetal heart rate (FHR) and serum free beta-human chorionic gonadotropin (beta-hCG) and pregnancy-associated plasma protein A (PAPP-A). METHOD Screening by the combined test was per...

BACKGROUND Abnormal levels of the markers AFP, hCG, and uE3 could be useful in predicting adverse pregnancy outcomes. This study was designed to determine the correlation between second trimester maternal serum markers and adverse pregnancy outcome (APO). METHODS In this historical cohort study, we randomly followed 231 obstetric patients with quadruple screening test in 14-18 weeks of gestat...

OBJECTIVE To evaluate the performance of a one-stop clinic for assessment of risk (OSCAR) for trisomy 21 by a combination of maternal age, fetal nuchal translucency (NT) thickness and maternal serum free beta-human chorionic gonadotropin (hCG) and pregnancy-associated plasma protein-A (PAPP-A) at 11-14 weeks of gestation. METHOD Screening for trisomy 21 was carried out by OSCAR in 15 030 sing...

OBJECTIVES The aim of this study was to investigate the effectiveness of erythromycin in preventing fetal and intrauterine group B streptococcal (GBS) infections. The study evaluated the penetration of erythromycin through the placenta, by comparing umbilical vein and maternal serum erythromycin concentrations. MATERIAL AND METHODS The study subjects were 42 pregnant women, with GBS-positive ...

Fetal serum markers, such as alpha fetoprotein (AFP), must traverse one of two very different pathways to reach maternal serum, either from fetus to amnion fluid, membranes and decidua or from fetal to maternal circulation through the placental villi. Alpha fetoprotein usually enters the amnion fluid through body wall defects uncovered by skin or through urine. Placental AFP leakage may be from...

OBJECTIVE To review the obstetrical outcomes associated with abnormally elevated or decreased level of one or more of the most frequently measured maternal serum marker analytes used in screening for aneuploidy. To provide guidance to facilitate the management of pregnancies that have abnormal levels of one of more markers and to assess the usefulness of these markers as a screening test. OPT...

Maternal serum analyte screening is an integral component of contemporary antenatal care. Based on elevated MSAFP levels, 85% to 90% of NTDs (e.g., anencephaly or spina bifida) can be detected. Using a combination of serum analytes (e.g., MSAFP, hCG, UE3) 55% to 60% of fetal Down's syndrome can be detected. Future strategies for Down's syndrome screening may include the use of new markers such ...